An Introduction to Lymphoma
Lymphoma is one of the ten most common malignancies worldwide. While some lymphomas are curable, the treatment of relapsed and refractory disease remains a substantial challenge. Recent advances have led to the development of a number of new treatment strategies, including novel antibodies targeting surface antigens, small molecular inhibitors targeting oncogenic signalling pathways and tumour suppressors, and immune checkpoint inhibitors. Chimeric antigen receptor (CAR) T-cells offer the potential for personalised therapy. The emergence of so many new therapeutic options have raised challenges in terms of optimal sequencing and combined approaches, and have highlighted the need for biomarkers to predict therapeutic response.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: An expert interview with Umberto Vitolo
Umberto Vitolo is a Haematology Consultant, Candiolo Cancer Institute, Fondazione del Piemonte per l’Oncologia, IRCCS, Candiolo (Torino), Italy. His research interests are haematological malignancies, primarily lymphoma. He is a member of the Italian Society of Haematology, the Italian Society of Experimental Haematology and the American Society of Haematology. He has authored many papers in peer-reviewed […]
Jennifer Brown, ASH 2022: Zanubrutinib for patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma, ALPINE (phase III) results
The ALPINE study in patients with relapsed/refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma has shown that zanubrutinib may offer potential advantages over ibrutinib. In this touchONCOLOGY interview, we speak with Dr Jennifer Brown (Dana-Farber Cancer Institute, Boston, MA, USA) to discuss the mechanism of action of zanubrutinib, its potential advantages over ibrutinib and the […]
William Townsend, EHA 2022: Final analysis of the GALLIUM study of obinutuzumab plus chemotherapy in follicular lymphoma
Dr William Townsend shares the latest data from the final analysis of the phase III GALLIUM study, which used the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab plus chemotherapy to follicular lymphoma. The study compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma. The abstract ‘OBINUTUZUMAB PLUS CHEMOTHERAPY DEMONSTRATES LONG-TERM […]
PART TWO: Mazyar Shadman, EHA 2022: MB-106 for the treatment of relapsed/refractory follicular lymphoma: Results of the phase I/II study
In Part Two of this interview, Dr Mazyar Shadman (Fred Hutchinson Cancer Center, Seattle, Was, USA) presents the results of the follicular lymphoma cohort from his ongoing phase I/II clinical trial investigating MB-106 for B-cell lymphoma/CLL. He discusses the positive efficacy and safety data and the next steps in the clinical development of MB-106. Abstract […]
PART ONE: Mazyar Shadman, EHA 2022: MB-106 for the treatment of relapsed/refractory follicular lymphoma.
In part one of this interview, Dr Mazyar Shadman (Fred Hutchinson Cancer Center, Seattle, Was, USA) discusses the challenges of CAR-T therapy for follicular lymphoma and the advantages of MB-106, a third-generation, CD20-targeted, autologous CAR-T cell therapy over earlier generation CAR-T therapies. Abstract S207: ‘EFFICACY AND SAFETY OF A THIRD GENERATION CD20 CART (MB-106) FOR […]
Stephen Ansell, ASCO 2022: ECHELON-1, brentuximab vedotin plus chemotherapy for classical Hodgkin lymphoma
The ECHELON-1 study compared the experimental brentuximab vedotin plus chemotherapy (A+AVD) to standard ABVD chemotherapy in patients with classical Hodgkin lymphoma. Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses the design and findings of the study as well as what was learned and how this will impact the treatment paradigm. The abstract entitled ‘First-line […]
Stephen Ansell, ASCO 2022: Challenges and unmet treatment needs in Hodgkin lymphoma
Hodgkin lymphoma is a challenging disease and a cure, with current therapy, is possible in some but not all patients. Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses these challenges and the unmet needs in the treatment of Hodgkin lymphoma. Dr Stephen Ansell presented an abstract entitled ‘First-line brentuximab vedotin plus chemotherapy to improve […]
CAR T-cell treatment pathway: From patient identification to long-term management
Watch leading experts discuss CAR T-cell treatment pathways in non-Hodgkin lymphoma and multiple myeloma, from patient identification to long-term management.
Current and Future Therapies for Marginal Zone Lymphoma
touchREVIEWS in Oncology & Haematology 2022;18(1):40–3 DOI: https://doi.org/10.17925/OHR.2022.18.1.40
Marginal zone lymphoma subtypes Marginal zone lymphoma (MZL) is an indolent non-Hodgkin lymphoma (NHL) that accounts for 5.0%–10.0% of NHLs.1 There are three subtypes of MZL: extranodal (including mucosa-associated lymphoid tissue [MALT]), splenic and nodal.1 Extranodal MZL (EMZL) is the most common type of MZL and accounts for about 70% of all cases of MZLs, occuring in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!